280 related articles for article (PubMed ID: 20444732)
1. CDX2 and LI-cadherin expression in esophageal mucosa: use of both markers can facilitate the histologic diagnosis of Barrett's esophagus and carcinoma.
Weimann A; Zimmermann M; Gross M; Slevogt H; Rieger A; Morawietz L
Int J Surg Pathol; 2010 Oct; 18(5):330-7. PubMed ID: 20444732
[TBL] [Abstract][Full Text] [Related]
2. Comparison of six immunohistochemical markers for the histologic diagnosis of neoplasia in Barrett's esophagus.
Weimann A; Rieger A; Zimmermann M; Gross M; Hoffmann P; Slevogt H; Morawietz L
Virchows Arch; 2010 Nov; 457(5):537-45. PubMed ID: 20844891
[TBL] [Abstract][Full Text] [Related]
3. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus.
Villanacci V; Rossi E; Zambelli C; Galletti A; Cestari R; Missale G; Casa DD; Bassotti G
Dig Liver Dis; 2007 Apr; 39(4):305-11. PubMed ID: 17307036
[TBL] [Abstract][Full Text] [Related]
4. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
Lord RV; Brabender J; Wickramasinghe K; DeMeester SR; Holscher A; Schneider PM; Danenberg PV; DeMeester TR
Surgery; 2005 Nov; 138(5):924-31. PubMed ID: 16291394
[TBL] [Abstract][Full Text] [Related]
5. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus.
Phillips RW; Frierson HF; Moskaluk CA
Am J Surg Pathol; 2003 Nov; 27(11):1442-7. PubMed ID: 14576477
[TBL] [Abstract][Full Text] [Related]
6. Liver-intestine-cadherin is a sensitive marker of intestinal differentiation during Barrett's carcinogenesis.
Mokrowiecka A; Zonnur S; Veits L; Musial J; Kordek R; Lochowski M; Kozak J; Malecka-Panas E; Vieth M; Hartmann A
Dig Dis Sci; 2013 Mar; 58(3):699-705. PubMed ID: 23053896
[TBL] [Abstract][Full Text] [Related]
7. Aberrant expression of CDX2 in Barrett's epithelium and inflammatory esophageal mucosa.
Eda A; Osawa H; Satoh K; Yanaka I; Kihira K; Ishino Y; Mutoh H; Sugano K
J Gastroenterol; 2003; 38(1):14-22. PubMed ID: 12560917
[TBL] [Abstract][Full Text] [Related]
8. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
9. Cdx2 expression and its promoter methylation during metaplasia-dysplasia-carcinoma sequence in Barrett's esophagus.
Makita K; Kitazawa R; Semba S; Fujiishi K; Nakagawa M; Haraguchi R; Kitazawa S
World J Gastroenterol; 2013 Jan; 19(4):536-41. PubMed ID: 23382633
[TBL] [Abstract][Full Text] [Related]
10. Expression of CDX2 and MUC2 in Barrett's mucosa.
Steininger H; Pfofe DA; Müller H; Haag-Sunjic G; Fratianu V
Pathol Res Pract; 2005; 201(8-9):573-7. PubMed ID: 16259110
[TBL] [Abstract][Full Text] [Related]
11. CDX2 and villin are useful markers of intestinal metaplasia in the diagnosis of Barrett esophagus.
Shi XY; Bhagwandeen B; Leong AS
Am J Clin Pathol; 2008 Apr; 129(4):571-7. PubMed ID: 18343784
[TBL] [Abstract][Full Text] [Related]
12. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
[TBL] [Abstract][Full Text] [Related]
13. Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas.
Washington K; Chiappori A; Hamilton K; Shyr Y; Blanke C; Johnson D; Sawyers J; Beauchamp D
Mod Pathol; 1998 Sep; 11(9):805-13. PubMed ID: 9758359
[TBL] [Abstract][Full Text] [Related]
14. CDX2, COX2 and MUC2 expressions in Barrett's esophagus: can they be useful in determination of the dysplasia?
Türkmen IÇ; Başsüllü N; Uraz S; Yerdel MA; Memışoğlu R; Bülbül Doğusoy G
Turk Patoloji Derg; 2012; 28(3):251-8. PubMed ID: 23011828
[TBL] [Abstract][Full Text] [Related]
15. Intestinal metaplasia in Barrett's oesophagus may be an epiphenomenon rather than a preneoplastic condition, and CDX2-positive cardiac-type epithelium is associated with minute Barrett's tumour.
Watanabe G; Ajioka Y; Takeuchi M; Annenkov A; Kato T; Watanabe K; Tani Y; Ikegami K; Yokota Y; Fukuda M
Histopathology; 2015 Jan; 66(2):201-14. PubMed ID: 25040564
[TBL] [Abstract][Full Text] [Related]
16. Esophageal adenocarcinoma arising in cervical inlet patch with synchronous Barrett's esophagus-related dysplasia.
Tanaka M; Ushiku T; Ikemura M; Shibahara J; Seto Y; Fukayama M
Pathol Int; 2014 Aug; 64(8):397-401. PubMed ID: 25143128
[TBL] [Abstract][Full Text] [Related]
17. Pericentriolar material analyses in normal esophageal mucosa, Barrett's metaplasia and adenocarcinoma.
Segat D; Cassaro M; Dazzo E; Cavallini L; Romualdi C; Salvador R; Vitale MP; Vitiello L; Fassan M; Rugge M; Zaninotto G; Ancona E; Baroni MD
Histol Histopathol; 2010 May; 25(5):551-60. PubMed ID: 20238294
[TBL] [Abstract][Full Text] [Related]
18. E-cadherin expression in gastroesophageal reflux disease, Barrett's esophagus, and esophageal adenocarcinoma: an immunohistochemical and immunoblot study.
Swami S; Kumble S; Triadafilopoulos G
Am J Gastroenterol; 1995 Oct; 90(10):1808-13. PubMed ID: 7572899
[TBL] [Abstract][Full Text] [Related]
19. CDX2 co-localizes with liver-intestine cadherin in intestinal metaplasia and adenocarcinoma of the stomach.
Ko S; Chu KM; Luk JM; Wong BW; Yuen ST; Leung SY; Wong J
J Pathol; 2005 Apr; 205(5):615-22. PubMed ID: 15732140
[TBL] [Abstract][Full Text] [Related]
20. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
Feith M; Stein HJ; Mueller J; Siewert JR
Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
